Hikma Pharmaceuticals plc
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Hikma Pharmaceuticals plc
“A lot of companies are hurting because of the higher interest rates,” one major CEO observed recently, summing up a year which saw little headline-grabbing news on the M&A front for generic and biosimilar sponsors.
Hikma’s recently installed CEO Riad Mishlawi told a packed room at the recent Jefferies 2024 London Healthcare Conference that Hikma had not reached a decision on pursuing its Xyrem ANDA product.
Hyloris has announced US FDA approval for its Maxigesic IV innovative paracetamol/ibuprofen solution for infusion. The product is expected to launch in the US in early 2024 via marketing partner Hikma, under the name Combogesic IV.
As Sun Pharma announces a Canadian launch for its licensed Winlevi clascoterone cream dermatology asset, the firm’s originating partner Cassiopea has struck further deals with Hikma and Glenmark for the acne treatment to be sold in Europe, the MENA region and South Africa.
- Generic Drugs
- Specialty Pharmaceuticals
- Other Names / Subsidiaries
- Custopharm, Inc.
- EIMC United Pharmaceuticals
- Roxane Laboratories, Inc.
- West-Ward Pharmaceuticals Corp.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.